Form 4: West Pharma CFO's Scheduled Stock Vesting and Sale

West Pharmaceutical Services' CFO, Robert W. McMahon, acquired common stock through RSU vesting and subsequently sold a portion for tax obligations.

Summary

• Robert W. McMahon, SVP & Chief Financial Officer of West Pharmaceutical Services Inc. (WST), reported transactions on February 11, 2026.
• McMahon acquired 4,230.525 shares of common stock upon the vesting of restricted stock units (RSUs).
• Following the acquisition, McMahon disposed of 1,250.034 shares of common stock at a price of $246.16 per share, likely to cover tax liabilities associated with the RSU vesting.
• After these transactions, McMahon beneficially owns 2,980.491 shares of common stock directly.
• McMahon also beneficially owns 8,462.052 derivative securities, specifically restricted stock units, directly.
• The acquired common stock resulted from the first installment of a 12,670 RSU grant made on August 11, 2025, which vests in three tranches.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting routine executive compensation and the vesting of equity, which aligns management incentives with shareholder interests. The associated tax-related sale is a standard practice.

Positives

• The vesting of restricted stock units aligns management's interests with shareholders by providing equity compensation.
• The transaction represents a routine, pre-scheduled compensation event, indicating stability in executive compensation structure.

Negatives

• The disposition of 1,250.034 shares, while common for tax purposes, reduces the direct common stock ownership of the CFO.

Future Outlook

The remaining 8,462.052 restricted stock units held by the CFO are scheduled to vest in two future installments: 6,335 shares (plus dividend equivalents) on August 11, 2026, and 2,112 shares (plus dividend equivalents) on August 11, 2027.

Industry Context

StockSavvy.ai notes that equity compensation, particularly through restricted stock units, is a standard practice across the pharmaceutical and medical device industries to attract, retain, and incentivize key executives, aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a significant component of executive compensation is consistent with practices observed at peer companies in the healthcare and life sciences sectors, such as Thermo Fisher Scientific (TMO) and Danaher Corporation (DHR), which also utilize performance-based equity awards and time-based vesting schedules to incentivize leadership.
• The 'sell to cover' transaction for tax obligations upon RSU vesting is a common and expected practice for executives receiving equity compensation across all industries, including technology and manufacturing, and does not typically signal a change in management's outlook on the company's prospects.

Stakeholder Impact

• Shareholders: The vesting of RSUs for the CFO reinforces management's alignment with shareholder value creation through equity ownership, though the tax-related sale slightly reduces direct holdings.
• Employees: This transaction is part of a standard executive compensation package, which can serve as a benchmark or motivator for other employees with equity awards.

Next Steps

• The next vesting installment of 6,335 restricted stock units (plus dividend equivalents) is scheduled for August 11, 2026.
• The final vesting installment of 2,112 restricted stock units (plus dividend equivalents) is scheduled for August 11, 2027.

Key Dates

Keywords

West Pharmaceutical Services, WST, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Equity Compensation, CFO Stock Sale